United States Patent 6,342,476: Scope, Claims, and US Patent Landscape for Copolymer-1 Fraction Dosing in Multiple Sclerosis

What does US 6,342,476 claim in practical terms?

US 6,342,476 (assigned to a Copolymer-1 multiple sclerosis franchise) claims a specific method of treatment for multiple sclerosis using a specified copolymer-1 fraction plus a specific fraction-definition process. The claims tie therapeutic effect not just to “copolymer-1,” but to (i) molecular-weight distribution constraints, (ii) impurity/species constraints, and (iii) how the fraction is prepared, using protected copolymer-1 processed through a trifluoroacetylation step followed by aqueous piperidine deprotection.

The single independent claim (Claim 1) can be reduced to three enforceable pillars: dose, fraction specifications, and fraction manufacture.

Claim 1: enforceable pillars

Pillar A: Therapeutic use (method claim)

Method for treating multiple sclerosis.
Administer a “pharmaceutically effective amount” to a subject in need.

Pillar B: Fraction specifications (what must be in the administered material)

The copolymer-1 fraction contains:
- Less than 5% of “species of copolymer-1 having molecular weight over 40 kilodaltons.”
- Over 75% of copolymer-1 in the fraction is in a molecular weight range of about 2 kDa to about 20 kDa.

Pillar C: Fraction preparation process (how the administered fraction is made)

The copolymer-1 fraction is prepared by reacting:
1. Protected copolymer-1 with hydrobromic acid to form trifluoroacetyl copolymer-1.
  - The trifluoroacetyl copolymer-1 must have over 75% of its molar fraction within 2 kDa to 20 kDa.
  - Reaction time and temperature are “predetermined by test reaction.”
2. Treat the resulting trifluoroacetyl copolymer-1 with aqueous piperidine solution to form copolymer-1.
  - The resulting copolymer-1 must have over 75% of its molar fraction within 2 kDa to 20 kDa.

This structure means the claim is not satisfied by any copolymer-1 composition; it requires a molecular-weight-profiled fraction plus manufacturing steps that achieve that profile.

How is the scope actually constrained?

Molecular weight cutoffs and thresholds are tight

The claim sets three hard numeric thresholds:

Low high-MW tail: <5% of copolymer-1 species with molecular weight >40 kDa.
Dominant mid-MW body: >75% molar fraction in 2-20 kDa.
Process outcomes: the trifluoroacetyl intermediate and the final copolymer-1 both must each satisfy the >75% in 2-20 kDa requirement.

This creates a scope that is narrower than “copolymer-1” broadly, and narrower than “enriched low molecular weight copolymer-1” generally.

“About” provides some leeway, but not full freedom

Both the 2 kDa and 20 kDa bounds are “about,” giving the patentee room for manufacturing variability. The magnitude of that “about” is typically argued through examples, analytical methods, and prosecution history. Without the specification text, the cleanest actionable takeaway is that the claim is still anchored on a 2-20 kDa dominant distribution and a <5% >40 kDa tail.

Process language narrows potential design-arounds

The claim ties the fraction to a process:

Protected copolymer-1 + hydrobromic acid to form trifluoroacetyl copolymer-1 (with the required distribution).
Then aqueous piperidine to form copolymer-1 (with the required distribution).

Even if a competitor could make a final fraction matching the numeric distribution, infringement risk increases if their process uses the same two-step chemical logic (hydrobromic acid forming the trifluoroacetyl intermediate, then aqueous piperidine deprotection).

What parts are “likely to be fought” during infringement analysis?

1) Molecular weight distribution measurement

Key infringement facts will be:

Whether the administered fraction’s “molar fraction” distribution is measured and meets:
- 75% between 2-20 kDa, and
- <5% above 40 kDa.

Because the claim uses molar fraction, a typical dispute is which analytical technique defines “molar fraction” and how peak deconvolution is done.

2) Identity of the administered entity

The claim requires “a copolymer-1 fraction wherein…” meaning the product as administered must be that fraction. If a commercial product contains additional components, salts, carriers, or excipients, infringement still turns on whether the copolymer-1 fraction contained in that product meets the numeric constraints.

3) Process linkage to the administered fraction

The claim’s process language (“is prepared by a process comprising…”) can be litigated as:

a product-by-process element,
or a limitation that must be shown for the asserted infringing product.

Either way, manufacturing documentation, batch records, and chemistry descriptions become core evidence.

How broad is the claim against potential design-arounds?

A design-around strategy has two general axes: product specification and process deviation.

Product-specification design-arounds

A competitor can attempt to avoid:

>75% in 2-20 kDa by shifting the distribution.
<5% above 40 kDa by maintaining more high-MW material.

However, these adjustments may affect safety, efficacy, solubility, or manufacturability, and can collide with other patents or data packages in the MS copolymer program.

Process-design-arounds

The claim specifies:

hydrobromic acid reaction producing a “trifluoroacetyl copolymer-1” intermediate
followed by aqueous piperidine treatment.

A competitor could avoid infringement by changing both the intermediate formation chemistry and deprotection logic. If the competitor achieves the same final molecular distribution but via different chemistry, the “product-by-process” nature of the limitation becomes decisive in litigation posture.

Where does this claim sit in the larger copolymer-1 MS patent landscape?

The claim targets a “low molecular weight fraction” concept

This claim aligns with the broader industry strategy seen across copolymer-1 programs: tailoring pharmacological properties by controlling molecular-weight distribution. The numeric thresholds indicate the inventors used distribution targeting, not just nominal “low MW” categories.

It targets manufacturing steps that create a defined distribution

The trifluoroacetyl intermediate and aqueous piperidine step indicate a specific synthetic route from protected copolymer-1. This route likely relates to how earlier copolymer-1 compositions were produced and refined for MS activity.

It is a method-of-use claim with a process-formed product limit

The combination (method of treatment + product fraction spec + process) creates a layered enforcement structure:

competitors must avoid the method using the specified fraction,
and must avoid making or administering a fraction produced by the defined route.

That is typically a strong position when multiple versions of a product exist in the market, and when manufacturing steps can be evidenced.

US enforcement-relevant timeline and landscape signals

This patent is US 6,342,476. Without the full bibliographic record (filing date, expiration due to term adjustments, priority chain, and maintenance status), only structural statements can be made from Claim 1 itself:

The claim is tightly drafted for fraction specs and manufacturing chemistry, consistent with a later-generation refinement of copolymer-1 dosing and preparation.
In a copolymer-1 MS landscape, this type of claim often overlaps with:
- earlier foundational copolymer-1 composition claims,
- later refinements of molecular-weight fractionation or enrichment,
- and manufacturing process improvements.

The practical enforcement window depends on the expiration and any terminal disclaimers, PTA, or related continuation filings, which are not provided in the prompt.

Practical freedom-to-operate (FTO) implications for developers and biosimilar-style operators

If the target is a copolymer-1 MS product with a controlled MW distribution

Key diligence items tied to this claim:

Specification of the administered copolymer-1 fraction’s MW distribution:
- Confirm >75% molar fraction in 2-20 kDa.
- Confirm <5% above 40 kDa.
Chemistry route used to prepare the fraction:
- Whether protected copolymer-1 is treated with hydrobromic acid to form a trifluoroacetyl intermediate.
- Whether aqueous piperidine is used for conversion to copolymer-1.
Batch records and intermediate analytical results:
- trifluoroacetyl intermediate distribution must also meet the >75% 2-20 kDa requirement.

Most at-risk scenarios

Manufacturing partners that use the same hydrobromic acid / trifluoroacetyl intermediate / aqueous piperidine logic and deliver a fraction meeting the exact distribution thresholds.
Clinical or commercial formulations where the copolymer-1 component is characterized and released under MW distribution targets that mirror the claim.

Claim 1 element map (for infringement design and claim charting)

Claim Element	Concrete Requirement	What Evidence Will Matter
Treatment method	Treat multiple sclerosis by administering a pharmaceutically effective amount	Clinical protocol, labeling, and product administration
Fraction MW distribution	<5% species with MW >40 kDa	Product specs, chromatography/SEC data, molar fraction calculations
Fraction dominant range	>75% molar fraction in 2-20 kDa	Release tests and method validation
Protected copolymer-1 step	React protected copolymer-1 with hydrobromic acid to form trifluoroacetyl copolymer-1	SOPs, batch records, intermediate identity tests
Intermediate distribution	trifluoroacetyl intermediate has >75% molar fraction in 2-20 kDa	Intermediate analytical results
Test-determined conditions	Reaction time and temperature “predetermined by test reaction”	Pilot/test data, batch parameter selection rationale
Deprotection step	Treat trifluoroacetyl copolymer-1 with aqueous piperidine to form copolymer-1	Conversion records, piperidine concentration/time
Final distribution again	Final copolymer-1 has >75% molar fraction in 2-20 kDa	Final product analytics

Key Takeaways

US 6,342,476 claims a multiple sclerosis treatment method that depends on administering a copolymer-1 fraction meeting strict molecular-weight distribution limits: >75% in 2-20 kDa and <5% above 40 kDa.
The claim also locks the fraction to a two-step manufacturing route: hydrobromic acid conversion of protected copolymer-1 to a trifluoroacetyl copolymer-1 intermediate, followed by aqueous piperidine treatment to yield the final copolymer-1 fraction, with the distribution requirement satisfied at both intermediate and final stages.
The scope is materially narrower than generic copolymer-1 use; design-arounds need to disrupt either the numeric MW distribution or the specified process pathway (or both), and proof will center on MW measurement methods and batch/analytical documentation for intermediate and final products.

FAQs

1) Is this a composition claim or a method claim?
It is a method for treating multiple sclerosis, but it requires administering a specific fraction and ties that fraction to a defined process used to prepare it.

2) What are the two most important numeric constraints in Claim 1?
<5% of copolymer-1 species with MW over 40 kDa, and >75% of copolymer-1 in the fraction within about 2 kDa to about 20 kDa.

3) Does the claim require the trifluoroacetyl intermediate to meet the MW profile too?
Yes. It requires the trifluoroacetyl copolymer-1 to have over 75% molar fraction in about 2 kDa to about 20 kDa and requires the final copolymer-1 to meet the same distribution.

4) Can a competitor avoid infringement by changing only the dosing amount?
No. Even a pharmaceutically effective dose does not avoid infringement if the administered copolymer-1 fraction meets the claimed MW distribution and is prepared by the claimed process.

5) What is the enforcement-critical documentation for litigation or FTO?
Batch records and validated analytical data showing (i) final MW distribution (<5% >40 kDa and >75% 2-20 kDa by molar fraction) and (ii) that the hydrobramic-acid and aqueous piperidine steps produce intermediates and final material meeting the same distribution limits.

References

[1] United States Patent 6,342,476. Claims (Claim 1 as provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0762888	⤷ Start Trial	90987	Luxembourg	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300096	Netherlands	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300251	Netherlands	⤷ Start Trial
Austria	212857	⤷ Start Trial
Australia	1016102	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,342,476

Summary for Patent: 6,342,476